Assets
| Type | Time | Amount | Unit |
|---|---|---|---|
| ifrs-full:Assets | 2020-12-31 | 584971435 | vDKK |
| ifrs-full:Assets | 2020-12-31 | 149608000 | vDKK |
| ifrs-full:Assets | 2020-12-31 | 130040000 | vDKK |
| ifrs-full:Assets | 2020-12-31 | 124799000 | vDKK |
| ifrs-full:Assets | 2019-12-31 | 149607513 | vDKK |
Revenue
| Type | Start date | End date | Amount | Unit |
|---|---|---|---|---|
| ifrs-full:Revenue | 2020-01-01 | 2020-12-31 | 330145351 | vDKK |
| ifrs-full:Revenue | 2020-01-01 | 2020-12-31 | 363936000 | vDKK |
| ifrs-full:Revenue | 2020-01-01 | 2020-12-31 | 341939000 | vDKK |
| ifrs-full:Revenue | 2020-01-01 | 2020-12-31 | 317443000 | vDKK |
| ifrs-full:Revenue | 2019-01-01 | 2019-12-31 | 363935810 | vDKK |
XML
See the xml submitted here:
XML: http://regnskaber.virk.dk/54008183/amNsb3VkczovLzAzLzM1LzZkLzE5L2Y0LzFhMzMtNDFmMC05NzA5LTFmNTVkMGI3NmY2ZA.xml
Separator
The full data:
<?xml version="1.0" encoding="UTF-8"?><!-- Version: 1.1.1028.0 --><!-- Document created: 20-05-2021 11:06:08 --><!-- Created by: XBRL Wizard, EasyX --><xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:entry="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature" xmlns:gsd="http://xbrl.dcca.dk/gsd" xmlns:tax="http://xbrl.dcca.dk/tax" xmlns:tch="http://xbrl.dcca.dk/tch" xmlns:gen="http://xbrl.org/2008/generic" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:variable="http://xbrl.org/2008/variable" xmlns:eogs="http://xbrl.dcca.dk/eogs" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:dst="http://xbrl.dcca.dk/dst" xmlns:arr="http://xbrl.dcca.dk/arr" xmlns:valm="http://xbrl.org/2010/message/validation" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:msg="http://xbrl.org/2010/message" xmlns:fsa="http://xbrl.dcca.dk/fsa" xmlns:cmn="http://xbrl.dcca.dk/cmn" xmlns:label="http://xbrl.org/2008/label" xmlns:mrv="http://xbrl.dcca.dk/mrv" xmlns:esg="http://xbrl.dcca.dk/esg" xmlns:sob="http://xbrl.dcca.dk/sob" xsi:schemaLocation="http://xbrl.org/2006/xbrldi http://www.xbrl.org/2006/xbrldi-2006.xsd">
<link:schemaRef xlink:type="simple" xlink:href="http://archprod.service.eogs.dk/taxonomy/20201001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20201001.xsd"/>
<xbrli:context id="ctx1">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx2">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
<cmn:memberOfBoardIdentifier>0</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx3">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>0</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx4">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx5">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx6">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:PreviousYearMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx7">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:TwoYearsAgoMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx8">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:ThreeYearsAgoMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx9">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx10">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:PreviousYearMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx11">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:TwoYearsAgoMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx12">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:ThreeYearsAgoMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx13">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>0</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx14">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:PreviousYearMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>1</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx15">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:TwoYearsAgoMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>2</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx16">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:ThreeYearsAgoMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>3</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx17">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>4</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx18">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:PreviousYearMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>5</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx19">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:TwoYearsAgoMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>6</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx20">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:ThreeYearsAgoMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>7</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx21">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>8</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx22">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:PreviousYearMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>9</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx23">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:TwoYearsAgoMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>10</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx24">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:ThreeYearsAgoMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>11</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx25">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx26">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx27">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ResultDistributionDimension">fsa:ProposedExtraordinaryDividendRecognisedInEquityMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx28">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ResultDistributionDimension">fsa:ProposedExtraordinaryDividendRecognisedInEquityMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx29">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ResultDistributionDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx30">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ResultDistributionDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
<cmn:auditorIdentifier>0</cmn:auditorIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:unit id="vDKK">
<xbrli:measure>iso4217:DKK</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<fsa:ClassOfReportingEntity contextRef="ctx1">Regnskabsklasse C, mellemstor virksomhed</fsa:ClassOfReportingEntity>
<gsd:ReportingPeriodStartDate contextRef="ctx1">2020-01-01</gsd:ReportingPeriodStartDate>
<gsd:ReportingPeriodEndDate contextRef="ctx1">2020-12-31</gsd:ReportingPeriodEndDate>
<sob:StatementByExecutiveAndSupervisoryBoards contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Statement by the board of directors and executive board</td></tr></table></sob:StatementByExecutiveAndSupervisoryBoards>
<sob:IdentificationOfApprovedAnnualReport contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">The Board of Directors and the Executive Board have today discussed and approved the annual report of Novo Nordisk Denmark A/S for the financial year 1 January to 31 December 2020.</td></tr></table></sob:IdentificationOfApprovedAnnualReport>
<sob:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">The annual report has been presented in accordance with the Danish Financial Statements Act.</td></tr></table></sob:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement>
<sob:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">We consider the accounting policies used appropriate, and in our opinion the annual accounts provide a true and fair view of the Company's assets and liabilities and its financial position at 31 December 2020 and of the Company's results of its activities in the financial year 1 January to 31 December 2020.</td></tr></table></sob:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults>
<sob:ManagementsStatementAboutManagementsReview contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">In our opinion, the Management's review gives a fair review of the development in the company's operations and financial matters and the results of the company's operations and financial position.</td></tr></table></sob:ManagementsStatementAboutManagementsReview>
<sob:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">The annual report is recommended for approval by the general meeting.</td></tr></table></sob:RecommendationForApprovalOfAnnualReportByGeneralMeeting>
<sob:PlaceOfSignatureOfStatement contextRef="ctx1" xml:lang="da">Copenhagen</sob:PlaceOfSignatureOfStatement>
<sob:DateOfApprovalOfAnnualReport contextRef="ctx1">2021-04-15</sob:DateOfApprovalOfAnnualReport>
<arr:IndependentAuditorsReportsAudit contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Independent Auditor's Report</td></tr></table></arr:IndependentAuditorsReportsAudit>
<arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">To the shareholder of Novo Nordisk Denmark A/S</td></tr></table></arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements>
<arr:OpinionOnAuditedFinancialStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Opinion</td></tr><tr><td colspan="1">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2020 and of the results of the Company's operations and cash flows for the financial year I January to 31 December 2020 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan="1">We have audited the Financial Statements of Novo Nordisk Denmark A/S for the financial year 1 January to 31 December 2020, which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies.</td></tr></table></arr:OpinionOnAuditedFinancialStatements>
<arr:DescriptionOfQualificationsOfAuditedFinancialStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Basis for opinion</td></tr><tr><td colspan="1">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor 'a responsibilities for the audit of the Financial Statements section of our report". We are independent of the Company in accordance with international Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements its applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table></arr:DescriptionOfQualificationsOfAuditedFinancialStatements>
<arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Statement on Management's Review</td></tr><tr><td colspan="1">Management is responsible for Management's Review.</td></tr><tr><td colspan="1">Our opinion on the financial statements does not cover the Management's Review, and we do not express any form of assurance conclusion thereon.</td></tr><tr><td colspan="1">In connection with our audit of the financial statements, our responsibility is to read the Management's</td></tr><tr><td colspan="1">Review and, in doing so, consider whether the Management's Review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.</td></tr><tr><td colspan="1">Moreover, it is our responsibility to consider whether Management's Review provides the information required under the Danish Financial Statements Act.</td></tr><tr><td colspan="1">Based on the work we have performed, in our view, Management's Review is in accordance with the Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement in the Management's Review.</td></tr></table></arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements>
<arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Management's Responsibilities for the Financial Statement</td></tr><tr><td colspan="1">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan="1">In preparing the financial statements, Management is responsible for evaluating the Company's ability to continue as a going concern, disclosing, as applicablet, matters related to going concern and using the going concern basis of accounting when preparing the financial statements, unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table></arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements>
<arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Auditor's Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan="1">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements may arise from fraud or error and considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan="1">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan="1">â¢Â                Identify and assess the risks of material misstatement in the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan="1">â¢Â                Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan="1">â¢Â                 Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan="1">â¢Â               Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to. continue as a going concern.</td></tr><tr><td colspan="1">â¢Â                Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan="1">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in the internal control that we identify during our audit.</td></tr></table></arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed>
<arr:SignatureOfAuditorsPlace contextRef="ctx1" xml:lang="da">Hellerup</arr:SignatureOfAuditorsPlace>
<arr:SignatureOfAuditorsDate contextRef="ctx1">2021-04-15</arr:SignatureOfAuditorsDate>
<gsd:NameOfReportingEntity contextRef="ctx1" xml:lang="da">Novo Nordisk Denmark A/S</gsd:NameOfReportingEntity>
<gsd:AddressOfReportingEntityStreetName contextRef="ctx1" xml:lang="da">Ãrestads Boulevard</gsd:AddressOfReportingEntityStreetName>
<gsd:AddressOfReportingEntityStreetBuildingIdentifier contextRef="ctx1" xml:lang="da">108</gsd:AddressOfReportingEntityStreetBuildingIdentifier>
<gsd:AddressOfReportingEntityPostCodeIdentifier contextRef="ctx1" xml:lang="da">2300</gsd:AddressOfReportingEntityPostCodeIdentifier>
<gsd:AddressOfReportingEntityDistrictName contextRef="ctx1" xml:lang="da">København S</gsd:AddressOfReportingEntityDistrictName>
<gsd:TelephoneNumberOfReportingEntity contextRef="ctx1" xml:lang="da">+4535350002</gsd:TelephoneNumberOfReportingEntity>
<gsd:IdentificationNumberCvrOfReportingEntity contextRef="ctx1">38180045</gsd:IdentificationNumberCvrOfReportingEntity>
<gsd:DateOfFoundationOfReportingEntity contextRef="ctx1">2016-11-14</gsd:DateOfFoundationOfReportingEntity>
<gsd:RegisteredOfficeOfReportingEntity contextRef="ctx1" xml:lang="da">Copenhagen</gsd:RegisteredOfficeOfReportingEntity>
<gsd:DateOfGeneralMeeting contextRef="ctx1">2021-04-15</gsd:DateOfGeneralMeeting>
<gsd:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="ctx1" xml:lang="da">Thomas Haagen</gsd:NameAndSurnameOfChairmanOfGeneralMeeting>
<fsa:Revenue contextRef="ctx1" unitRef="vDKK" decimals="0">330145351</fsa:Revenue>
<fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx1" unitRef="vDKK" decimals="0">28207614</fsa:ProfitLossFromOrdinaryOperatingActivities>
<fsa:ResultsFromNetFinancials contextRef="ctx1" unitRef="vDKK" decimals="-3">-200000</fsa:ResultsFromNetFinancials>
<fsa:ProfitLoss contextRef="ctx1" unitRef="vDKK" decimals="0">21277960</fsa:ProfitLoss>
<fsa:InvestmentInPropertyPlantAndEquipment contextRef="ctx1" unitRef="vDKK" decimals="-3">29050000</fsa:InvestmentInPropertyPlantAndEquipment>
<fsa:AverageNumberOfEmployees contextRef="ctx1" unitRef="pure" decimals="2">152</fsa:AverageNumberOfEmployees>
<mrv:OperatingMargin contextRef="ctx1" unitRef="pure" decimals="3">0.085</mrv:OperatingMargin>
<mrv:GrossMargin contextRef="ctx1" unitRef="pure" decimals="3">0.836</mrv:GrossMargin>
<mrv:ReturnOnEquity contextRef="ctx1" unitRef="pure" decimals="3">0.819</mrv:ReturnOnEquity>
<mrv:EquityRatio contextRef="ctx1" unitRef="pure" decimals="3">0.063</mrv:EquityRatio>
<mrv:InformationOnCalculationOfKeyFiguresAndFinancialRatios contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="2">Financial ratios are calculated in accordance with the Danish Finance Society's recommendations on the calculation of financial ratios. For terms and definitions, please see the accounting policies.</td></tr><tr><td colspan="2">For 2020, Novo Nordisk Denmark A/S has implemented IFRS 16. As a result the annual report for the financial year of 2020 is presented in accordance with IFRS 16. This has led to an increase of assets before deprecation of T.DKK 11.694 and deprecations of T.DKK 3.103. Novo Nordisk Denmark A/S has chosen not to adjust the comparative figures with the implementation of IFRS I 6. For 2020, Novo Nordisk has also implemented IFRS IS. The implementation of IFRS 15 has not given any effect for 2020 or the comparative figures.</td></tr><tr><td colspan="2">The key figures appearing from the survey have been calculated as follows</td></tr><tr><td>Operating margin</td><td>Operating profit (EBIT) x 100 / Revenue</td></tr><tr><td>Gross margin ratio</td><td>Gross margin x 100 / Revenue</td></tr><tr><td>EBITDA-margin.</td><td>Earnings before interest taxes and amortisations x 100 / Revenue</td></tr><tr><td>Return on assets.</td><td>Results from primary activities (EBIT) x100 / Average assets</td></tr><tr><td>Current ratio.</td><td>Current assets x 100 / Short-term liabilities</td></tr><tr><td>Equity ratio</td><td>Equity, closing balance x 100 / Assets in total, closing balance</td></tr><tr><td>Return on equity</td><td>Results for the year x 100 / Average equity</td></tr></table></mrv:InformationOnCalculationOfKeyFiguresAndFinancialRatios>
<mrv:ManagementsReview contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Managements Review</td></tr><tr><td colspan="1">Business review</td></tr><tr><td colspan="1">Novo Nordisk Denmark A/S (secondary name Novo Nordisk Region Europe Pharmaceuticals A/S and Novo Nordisk North West Europe Pharmaceuticals A/S) is selling medicine in the treatment areas diabetes, obesity, growth and bleeding disorders as well as hormone replacement treatment. The company is located in Ãrestad in Copenhagen, Denmark. Number of average employees has increased from 65 in 2019 to 152 in 2020 since the Danish organisation in Novo Nordisk Scandinavia AB has been transferred to Novo Nordisk Denmark A/S.</td></tr><tr><td colspan="1">The impact from covid-19 has been limited since the need for medicine has been consistent. Production sites have been open during the year and we have been able to deliver the products to our patients. However, covid-19 resulted in lower travel activities as well as limited amounts of events and congresses.</td></tr><tr><td colspan="1">Novo Nordisk Denmark A/S consist of the following three organisations</td></tr><tr><td colspan="1">The Danish sales affiliate</td></tr><tr><td colspan="1">This unit was transferred from Novo Nordisk Scandinavia AB 1st of January 2020 and is now a part of Novo Nordisk Denmark A/S. Average number of employees in 2020 is 70. The unit is a fully operational sales affiliate with focus on the distribution of the medicine produced by Novo Nordisk A/S to patients in Denmark and Iceland. Novo Nordisk A/S (parent company) bears all the risks for launches and research &amp; development, hence launch costs and R&amp;D costs are invoiced to Novo Nordisk A/S as service fee including a mark-up for internal costs.</td></tr><tr><td colspan="1">North West Europe regional office</td></tr><tr><td colspan="1">Service company supporting the business areas/large affiliates in Europe (UK, France, Spain, Switzerland, Netherlands, Denmark, Sweden and business area North West Europe mid size). Average number of employees in 2020 is 66. All costs, both internal and external are invoiced to Novo Nordisk A/S as service fee including a mark-up for internal costs.</td></tr><tr><td colspan="1">North West Europe mid size business area office</td></tr><tr><td colspan="1">Service company supporting the affiliates in business area North West Europe mid size (Norway, Finland, Belgium, Austria, Portugal and Ireland). Average number of employees in 2020 is 17. All costs, both internal and external are invoiced to the affiliates in business area NWE mid size and to Novo Nordisk NS.</td></tr><tr><td colspan="1">Unusual matters having affected the financial statements</td></tr><tr><td colspan="1">The financial position at 31 December 2020 of the Company and the results of the activities of the Company for the financial year for 2020 have not been affected by any unusual matters.</td></tr><tr><td colspan="1">Financial review</td></tr><tr><td colspan="1">The revenue for the year is DKK 330.145.351 against DKK 363.935.810 last year. The results from ordinary activities after tax are DKK 21.277.960 against DKK 5.251.810 last year. The management consider the results satisfactory.</td></tr><tr><td colspan="1">Risks</td></tr><tr><td colspan="1">The risks in the company is limited since Novo Nordisk A/S bears all the risks for launches and research &amp; development. Hence all launch costs and R&amp;D costs are invoiced to Novo Nordisk A/S. All costs, both internal and external, for the regional office and the business area office are (due to a service contract) invoiced to Novo Nordisk A/S or to the affiliates in business area NWE mid size.</td></tr><tr><td colspan="1">Outlook</td></tr><tr><td colspan="1">Expectations for the coming years are expected to have positive development in sales and to follow the budgets prepared by the Finance and Operations function. For further information on products in pipeline and other developments areas, please read the annual report for the Novo Nordisk Group.</td></tr></table></mrv:ManagementsReview>
<fsa:OtherOperatingIncome contextRef="ctx1" unitRef="vDKK" decimals="0">492015498</fsa:OtherOperatingIncome>
<fsa:CostOfSales contextRef="ctx1" unitRef="vDKK" decimals="0">283762991</fsa:CostOfSales>
<fsa:OtherExternalExpenses contextRef="ctx1" unitRef="vDKK" decimals="0">262265462</fsa:OtherExternalExpenses>
<fsa:GrossResult contextRef="ctx1" unitRef="vDKK" decimals="0">276132396</fsa:GrossResult>
<fsa:EmployeeBenefitsExpense contextRef="ctx1" unitRef="vDKK" decimals="0">238729424</fsa:EmployeeBenefitsExpense>
<fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="ctx1" unitRef="vDKK" decimals="0">9195358</fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss>
<fsa:OtherFinanceIncome contextRef="ctx1" unitRef="vDKK" decimals="0">822093</fsa:OtherFinanceIncome>
<fsa:OtherFinanceExpenses contextRef="ctx1" unitRef="vDKK" decimals="0">1021898</fsa:OtherFinanceExpenses>
<fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx1" unitRef="vDKK" decimals="0">28007809</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
<fsa:TaxExpense contextRef="ctx1" unitRef="vDKK" decimals="0">6729849</fsa:TaxExpense>
<fsa:StatementOfChangesInEquity contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="5" align="left" valign="middle" >Statement of changes in equity</td></tr><tr><td colspan="5"></td></tr><tr><td width="100%" colspan="5" align="left" valign="middle" >All amounts in DKK</td></tr><tr><td width="15%" ></td><td width="17%" colspan="1" align="right" valign="middle" >Share capital</td><td width="22%" colspan="1" align="right" valign="middle" >Retained earnings</td><td width="22%" colspan="1" align="right" valign="middle" >Proposed dividend for the financial year</td><td width="24%" colspan="1" align="right" valign="middle" >Total</td></tr><tr><td width="15%" colspan="1" align="left" valign="middle" >Equity 1 January 2019</td><td width="17%" align="right" valign="middle" >500.000</td><td width="22%" align="right" valign="middle" >9.591.666</td><td width="22%" align="right" valign="middle" >0</td><td width="24%" align="right" valign="middle" >10.091.666</td></tr><tr><td colspan="5"></td></tr><tr><td width="15%" colspan="1" align="left" valign="middle" >Profit or loss for the year brought forward</td><td width="17%" align="right" valign="middle" >0</td><td width="22%" align="right" valign="middle" >5.251.810</td><td width="22%" align="right" valign="middle" >0</td><td width="24%" align="right" valign="middle" >5.251.810</td></tr><tr><td width="15%" colspan="1" align="left" valign="middle" >Equity 1 January 2020</td><td width="17%" align="right" valign="middle" >500.000</td><td width="22%" align="right" valign="middle" >14.809.405</td><td width="22%" align="right" valign="middle" >0</td><td width="24%" align="right" valign="middle" >15.309.405</td></tr><tr><td colspan="5"></td></tr><tr><td width="15%" colspan="1" align="left" valign="middle" >Profit or loss for the year brought forward</td><td width="17%" align="right" valign="middle" >0</td><td width="22%" align="right" valign="middle" >277.960</td><td width="22%" align="right" valign="middle" >21.000.000</td><td width="24%" align="right" valign="middle" >21.277.960</td></tr><tr><td width="15%" ></td><td width="17%" align="right" valign="middle" >500.000</td><td width="22%" align="right" valign="middle" >15.087.365</td><td width="22%" align="right" valign="middle" >21.000.000</td><td width="24%" align="right" valign="middle" >36.587.365</td></tr></table></fsa:StatementOfChangesInEquity>
<fsa:InformationOnReportingClassOfEntity contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">The annual report for Novo Nordisk Denmark A/S is presented in accordance with those regulations of the Danish Financial Statements Act concerning companies identified as class C enterprises (medium sized enterprises).</td></tr></table></fsa:InformationOnReportingClassOfEntity>
<fsa:ExplanationOfOtherMethodsOfRecognitionAndMeasurementBasisForAssetsInPreviousPeriod contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">The accounting policies used are unchanged compared to last year except for the accounting policies regarding IFRS 16</td></tr></table></fsa:ExplanationOfOtherMethodsOfRecognitionAndMeasurementBasisForAssetsInPreviousPeriod>
<fsa:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">The annual accounts are presented in Danish kroner (DKK).</td></tr></table><br><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Recognition and measurement in general</td></tr><tr><td colspan="1">The Financial Statements have been prepared under the historical cost method.</td></tr><tr><td colspan="1">Income is recognised in the profit and loss account concurrently with its realisation, including the recognition of value adjustments of financial assets and liabilities. Likewise, all costs, these including depreciation, amortisation, writedown, provisions, and reyersals which are due to changes in estimated amounts previously recognised in the profit and loss account are recognised in the profit and loss account</td></tr><tr><td colspan="1">Assets are recognised in the balance sheet when the company is liable to achieve future, financial benefits and the value of the asset can be measured reliably.</td></tr><tr><td colspan="1">Liabilities are recognised in the balance sheet when the company is liable to lose future, financial benefits and the value of the liability can be measured reliably.</td></tr><tr><td colspan="1">At the first recognition, assets and liabilities are measured at cost. Later, assets and liabilities are measured as described below for each individual accounting item.</td></tr><tr><td colspan="1">At recognition and measurement, such predictable losses and risks are taken into consideration, which may appear before the annual report is presented, and which concerns matters existing on the balance sheet date.</td></tr></table></fsa:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies>
<fsa:ExplanationOfNotDisclosingCashFlowsStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Pursuant to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the enterprise has been prepared, as the relevant information is included in the consolidated annual accounts for the higher-ranking parent company Novo Nordisk A/S.</td></tr></table></fsa:ExplanationOfNotDisclosingCashFlowsStatements>
<fsa:InformationOnNoncomparabilityOrRestatement contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Change of accounting policies regarding IFRS 16</td></tr><tr><td colspan="1">For 2020, Novo Nordisk Denmark A/S has implemented IFRS 16. As a result the annual report for the financial year of 2020 is presented in accordance with IFRS 16. This has led to an increase of assets before deprecation of T.DKK 11.694 and deprecations of T.DKK 3.103. Novo Nordisk Denmark A/S has choosen not to adjust the comparative figures with the implementation of IFRS 16.</td></tr><tr><td colspan="1">With effect from 1 January 2020, Novo Nordisk Denmark A/S consequently recognises_right-of use assets and lease liabilities at the commencement of the leasing arrangement. The assets are included as part of property, plant and equipment in note 7 and the liabilities as part of the leasing liabilities in note 12.</td></tr><tr><td colspan="1">By adopting IFRS 16, Novo Nordisk Denmark A/S has applied the modified retrospective approach with no adjustment of the comparative figures as permitted by the Standard.</td></tr><tr><td colspan="1">Novo Nordisk Denmark A/S has taken advantage of certain practical approaches available according to the standard. Therefore, previously concluded leases have not been reassessed at the date of implementation. Instead, the use allowance is set equal to the lease obligation adjusted for prepayments.</td></tr><tr><td colspan="1">In addition, as part of the implementation, Novo Nordisk Denmark A/S has</td></tr><tr><td colspan="1">- applied a single discount rate to portfolios of leases with reasonably similar characteristics</td></tr><tr><td colspan="1">- has assessed whether individual leases are onerous prior to applying the Standard</td></tr><tr><td colspan="1">- has applied hindsight in determining the lease term if the contract contains options to extend or terminate the lease</td></tr><tr><td colspan="1">- has not applied the capitalisation requirements of the Standard to leases for which the lease term ends within 12 months of the date of initial application.</td></tr><tr><td colspan="1">Novo Nordisk Denmark A/S will continue to report recognised assets and liabilities under leases within tangible fixed assets rather than show these as separate items on the balance sheet.</td></tr><tr><td colspan="1">The adjustment made during 2020 has not affected the equity. See note 13 for the effect on the balance sheet as of 1 January 2020.</td></tr></table></fsa:InformationOnNoncomparabilityOrRestatement>
<fsa:DescriptionOfMethodsOfForeignCurrencies contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Translate In foreign currency</td></tr><tr><td colspan="1">Transactions in foreign currency are translated by using the exchange rate prevailing 11 the date of the transaction. Differences in the rate of exchange arising between the rate at the date of transaction and the rate at the date of payment are recognised in the profit and loss account as an item under net financials.</td></tr><tr><td colspan="1">Debtors, creditors, and other monetary items in foreign currency are translated using the closing rate. The difference between the closing rate and the rate at the time of the occurrence or recognition in the latest annual accounts of the amount owed or the liability recognized in the profit and loss account under financial income and expenses.</td></tr></table></fsa:DescriptionOfMethodsOfForeignCurrencies>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Revenue</td></tr><tr><td colspan="1">Revenue consist of the net sales of pharmaceutical products sold to patients during the reporting period.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingIncomeAndExpenses contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Other operating Income</td></tr><tr><td colspan="1">Other operating income is related to invoiced service fees to Novo Nordisk A/S and Novo Nordisk Healthcare AG which consist of the income from the rendering of services is recognised as revenue as the services are rendered.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingIncomeAndExpenses>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Cost of sales</td></tr><tr><td colspan="1">Costs of sales includes costs of goods sold.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Other external expenses</td></tr><tr><td colspan="1">Other external costs comprise costs for distribution, sales, advertisement, administration, premises, loss on debtors, and operational leasing costs.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Staff costs</td></tr><tr><td colspan="1">Staff costs include salaries and wages including holiday allowances, pensions and other costs for social security etc. for staff members. Staff costs are less public reimbursements.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense>
<fsa:DescriptionOfMethodsOfImpairmentLossesAndDepreciation contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Depreciation</td></tr><tr><td colspan="1">Depreciation, amortisation and writedown comprise depreciation on, amortisation of and writedown relating to intangible and tangible fixed assets respectively.</td></tr></table></fsa:DescriptionOfMethodsOfImpairmentLossesAndDepreciation>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Financial income and expenses</td></tr><tr><td colspan="1">Financial income and expenses are recognised in the income statement with the amounts concerning the financial year. Financial income and expenses comprise interest income and expenses. financial expenses from financial leasing and reimbursements under the advance tax scheme, etc.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Tax of the results for the year</td></tr><tr><td colspan="1">The tax for the year comprises the current tax for the year and the changes in deferred ta-x, and it is recognised in the profit and loss account with the share referring to the results for the year and directly in the equity with the share referring to entries directly on the equity.</td></tr><tr><td colspan="1">The entity is jointly taxed with other group entities. The total Danish income tax charge is allocated between profit/loss-making Danish entities in proportion to their taxable income (full absorption).</td></tr><tr><td colspan="1">Jointly taxed entities entitled to a tax refund arc reimbursed by the management company based on the rates applicable to interest allowances, and jointly taxed entities wich have paid too little tax pay a surcharge according to the rates applicable to interest surcharges to the management company.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="2">Fixed assets</td></tr><tr><td colspan="2">Fixed assets are measured at cost with deduction of accrued depreciation and writedown.</td></tr><tr><td colspan="2">The depreciable amount is cost less any expected residual value after the end of the useful life of the asset. The amortisation period and the residual value are determined at the acquisition date and reassessed annually. If the residual value exceeds the carrying amount, the depreciation is discontinued.</td></tr><tr><td colspan="2">If the amortisation period or the residual value is changed, the effect on amortisation will, in future, be recognised as a change in the accounting estimates.</td></tr><tr><td colspan="2">The cost comprises acquisition cost and costs directly associated with the acquisition until the time when the asset is ready for use.</td></tr><tr><td colspan="2">Depreciation is done on a straight-line basis according to an assessment of the expected useful life</td></tr><tr><td>Fixtures and furniture, other plant and equipment</td><td>Useful life 10 years</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment>
<fsa:DescriptionOfMethodsOfLeases contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Leases</td></tr><tr><td colspan="1">The enterprise will be applying IFRS 16 as its basis of interpretation for the recognition of classification and recognition of leases.</td></tr><tr><td colspan="1">Leases pertaining to property, plant, and equipment for which the enterprise has the right-of-use are recognised in the statement of financial position as right-of-use assets. The assets are, at initial recognition, measured at imputed cost, consisting of</td></tr><tr><td colspan="1">â¢Â                The imputed lease liability</td></tr><tr><td colspan="1">â¢Â                Any lease payments paid prior to - or on - the starting date, less any lease incentives received</td></tr><tr><td colspan="1">â¢Â                Any direct start-up costs</td></tr><tr><td colspan="1">â¢Â                Any restoring costs</td></tr><tr><td colspan="1">Hereafter, recognised leased assets are treated like the enterprise's remaining property, plant, and equipment.</td></tr><tr><td colspan="1">The right-of-use assets is depreciated using the straight-line method over the lease term.</td></tr><tr><td colspan="1">Lease liabilities are recognised in the statement of financial position as liabilities other than provision and are measured, at initial recognition, at the present value of lease payments payable over the lease term. This includes a purchase option in the event that the enterprise expects to purchase the right-of-use asset. When determining the present value, the internal rate of return or, alternatively, the enterprise's borrowing rate is applied as discount rate.</td></tr><tr><td colspan="1">Hereafter, the lease liability is treated like the remaining financial liabilities, i.e. at amortised cost.</td></tr><tr><td colspan="1">The interest element of the lease payments is recognised in the income statement over the contractual term.</td></tr><tr><td colspan="1">All other leas.es are regarded as operating leases. Payments in connection with operating leases and other lease agreements are recognised in the income statement for the term of the contract. The company's total liabilities concerning operating leases and lease agreements are recognised under contingencies, etc.</td></tr></table></fsa:DescriptionOfMethodsOfLeases>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Receivables</td></tr><tr><td colspan="1">Receivables are measured at amortised cost which usually corresponds to face value. In order to meet expected losses, writedown takes place at the net realisable value.</td></tr><tr><td colspan="1">An impairment loss is recognised if there is objektive evidence that a receivable or a group of receivables is impaired. If there is objektive evidence that an individual receivable has been impaired, an impairment loss is recognised on individual basis.</td></tr><tr><td colspan="1">Receivables in respect of which there is no objective evidence of individual impairment are tested for objective evidence of impairment on a portfolio basis. The portfolios are primarily based on the debtor's domicile end credit ratings in line with the Company's risk management policy. The objective evidence applied to portfolios is determined based on historical loss experience.</td></tr><tr><td colspan="1">Impairment losses are calculated as the difference between the carrying amount of the receivables and the present value of the expected cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable or portfolio is used as discount rate.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Prepayments</td></tr><tr><td colspan="1">Prepayments recognised under "Assets" comprises prepaid expenses regarding subsequent financial reporting years.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets>
<fsa:ExplanationOfEntitysDefinitionOfCashAndCashEquivalents contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Cash</td></tr><tr><td colspan="1">Cash comprise cash at bank and in hand.</td></tr></table></fsa:ExplanationOfEntitysDefinitionOfCashAndCashEquivalents>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEquity contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Equity</td></tr><tr><td colspan="1">Dividend</td></tr><tr><td colspan="1">Dividend expected to be distributed for the year is recognised as a separate item under equity.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEquity>
<fsa:DescriptionOfMethodsOfCurrentTaxReceivablesAndLiabilities contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Corporate tax and deferred tax</td></tr><tr><td colspan="1">Current tax receivable and tax liabilities are recognised in the balance sheet at the amount calculated on the basis of the expected taxable income for the year adjusted for tax on previous years' taxable income and prepaid taxes. Tax receivable and tax liabilities are set off to the extent that legal right of set-off exists and if the items are expected to be settled net or simultaneously.</td></tr></table></fsa:DescriptionOfMethodsOfCurrentTaxReceivablesAndLiabilities>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Deferred tax is measured on the basis of all temporary differences in assets and liabilities with a balance sheet focus.</td></tr><tr><td colspan="1">Deferred tax assets, including the tax value of tax losses eligible for carry-over, are recognised at the value at which they are expected to be realisable, either by settlement against tax of future earnings or by set-off in deferred tax liabilities within the same legal tax unit.</td></tr><tr><td colspan="1">Deferred tax is measured based on the tax rules and tax rates applying under the legislation on the balance sheet date and prevailing when the deferred tax is expected to be released as current tax.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Liabilities</td></tr><tr><td colspan="1">Financial liabilities related to borrowings are recognised at the received proceeds with the deduction of transaction costs incurred. In following periods, the financial liabilities are recognised at amortised cost, corresponding to the capitalised value by use of the effective interest. The difference between the proceeds and the nominal value is recognised in the profit and loss account during the term of the loan.</td></tr><tr><td colspan="1">Other liabilities are measured at amortised cost which usually corresponds to the nominal value.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions>
<fsa:DisclosureOfEmployeeBenefitsExpense contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="3" align="left" valign="middle" ></td></tr><tr><td colspan="3"></td></tr><tr><td width="100%" colspan="3" align="left" valign="middle" >Staff costs</td></tr><tr><td colspan="3"></td></tr><tr><td width="100%" colspan="3" align="left" valign="middle" >All amounts in DKK.</td></tr><tr><td colspan="3"></td></tr><tr><td width="24%" ></td><td width="37%" align="right" valign="middle" >2020</td><td width="39%" align="right" valign="middle" >2019</td></tr><tr><td colspan="3"></td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Salaries and wages</td><td width="37%" align="right" valign="middle" >194.036.248</td><td width="39%" align="right" valign="middle" >103.917.040</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Pensions</td><td width="37%" align="right" valign="middle" >16.794.676</td><td width="39%" align="right" valign="middle" >8.560.321</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Other social security costs</td><td width="37%" align="right" valign="middle" >1.096.631</td><td width="39%" align="right" valign="middle" >563.050</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Other staff costs</td><td width="37%" align="right" valign="middle" >26.801.869</td><td width="39%" align="right" valign="middle" >12.858.111</td></tr><tr><td width="24%" ></td><td width="37%" align="right" valign="middle" >238.729.424</td><td width="39%" align="right" valign="middle" >125.898.522</td></tr><tr><td colspan="3"></td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Average number of full-time employees</td><td width="37%" align="right" valign="middle" >152</td><td width="39%" align="right" valign="middle" >65</td></tr><tr><td colspan="3"></td></tr><tr><td width="100%" colspan="3" align="left" valign="middle" >By reference to section 98b(3), (ii), of the Danish Financial Statements Act. remuneration to Management is not disclosed.</td></tr><tr><td width="100%" colspan="3" align="left" valign="middle" >Incentive programmes</td></tr><tr><td width="100%" colspan="3" align="left" valign="middle" >Management participates In Novo Nordisk NS's incentive programme.</td></tr><tr><td colspan="3"></td></tr></table></fsa:DisclosureOfEmployeeBenefitsExpense>
<fsa:DisclosureOfOtherFinanceIncome contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="3" align="left" valign="middle" >Financial Income</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Interest income, group entities</td><td width="37%" align="right" valign="middle" >426.036</td><td width="39%" align="right" valign="middle" >137.597</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Other financial income</td><td width="37%" align="right" valign="middle" >395.472</td><td width="39%" align="right" valign="middle" >260.543</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Tax-exempted interest</td><td width="37%" align="right" valign="middle" >585</td><td width="39%" align="right" valign="middle" >0</td></tr><tr><td width="24%" ></td><td width="37%" align="right" valign="middle" >822.093</td><td width="39%" align="right" valign="middle" >398.140</td></tr><tr><td colspan="3"></td></tr></table></fsa:DisclosureOfOtherFinanceIncome>
<fsa:DisclosureOfOtherFinanceExpenses contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="3" align="left" valign="middle" >Financial expense</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Interest expenses, group entities</td><td width="37%" align="right" valign="middle" >280.818</td><td width="39%" align="right" valign="middle" >385.025</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Other financial expenses</td><td width="37%" align="right" valign="middle" >741.080</td><td width="39%" align="right" valign="middle" >524.513</td></tr><tr><td width="24%" ></td><td width="37%" align="right" valign="middle" >1.021.898</td><td width="39%" align="right" valign="middle" >909.538</td></tr><tr><td colspan="3"></td></tr></table></fsa:DisclosureOfOtherFinanceExpenses>
<fsa:DisclosureOfTaxExpenses contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="3" align="left" valign="middle" >Tax for the year</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Estimated tax charge for the year</td><td width="37%" align="right" valign="middle" >8.127.268</td><td width="39%" align="right" valign="middle" >2.231.614</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Deferred tax adjustments in the year</td><td width="37%" align="right" valign="middle" >-1.397.419</td><td width="39%" align="right" valign="middle" >816.215</td></tr><tr><td width="24%" ></td><td width="37%" align="right" valign="middle" >6.729.849</td><td width="39%" align="right" valign="middle" >3.047.829</td></tr><tr><td colspan="3"></td></tr></table></fsa:DisclosureOfTaxExpenses>
<fsa:DisclosureOfPropertyPlantAndEquipment contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="3" align="left" valign="middle" >Property, plant and equipment</td></tr><tr><td colspan="3"></td></tr><tr><td width="24%" ></td><td width="37%" colspan="1" align="right" valign="middle" >Land and property</td><td width="39%" colspan="1" align="right" valign="middle" >Fixtures and fittings, other plant and equipment</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Cost at 1. januar 2020</td><td width="37%" align="right" valign="middle" >0</td><td width="39%" align="right" valign="middle" >1.768.507</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Acquisitions/ Impact of implementation of IFRS 16</td><td width="37%" align="right" valign="middle" >15.716.825</td><td width="39%" align="right" valign="middle" >13.333.273</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Retirement</td><td width="37%" align="right" valign="middle" >0</td><td width="39%" align="right" valign="middle" >-191.641</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Cost at 31. december 2020</td><td width="37%" align="right" valign="middle" >15.716.825</td><td width="39%" align="right" valign="middle" >14.918.139</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Impairment losses and depreciation at I. januar 2020</td><td width="37%" align="right" valign="middle" >0</td><td width="39%" align="right" valign="middle" >438.766</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Depreciation</td><td width="37%" align="right" valign="middle" >5.537.134</td><td width="39%" align="right" valign="middle" >3.466.582</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Impairment losses and depreciation at 31, december 2020</td><td width="37%" align="right" valign="middle" >5.537.134</td><td width="39%" align="right" valign="middle" >3.905.348</td></tr><tr><td colspan="3"></td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Carrying amount at 31. december 2020</td><td width="37%" align="right" valign="middle" >10.179.691</td><td width="39%" align="right" valign="middle" >11.004.791</td></tr><tr><td colspan="3"></td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Lease assets are recognised at a carrying amount of</td><td width="37%" align="right" valign="middle" >10.179.691</td><td width="39%" align="right" valign="middle" >8.590.778</td></tr><tr><td colspan="3"></td></tr></table></fsa:DisclosureOfPropertyPlantAndEquipment>
<fsa:InformationOnCurrentDeferredTaxAssets contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="3" align="left" valign="middle" >Deferred tax asset</td></tr><tr><td width="24%" ></td><td width="37%" align="right" valign="middle" >2020</td><td width="39%" align="right" valign="middle" >2019</td></tr><tr><td colspan="3"></td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Deferred tax assets I January</td><td width="37%" align="right" valign="middle" >998.201</td><td width="39%" align="right" valign="middle" >1.814.417</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Deferred tax of the results for the year</td><td width="37%" align="right" valign="middle" >1.397.419</td><td width="39%" align="right" valign="middle" >-816.215</td></tr><tr><td width="24%" ></td><td width="37%" align="right" valign="middle" >2.395.620</td><td width="39%" align="right" valign="middle" >998.202</td></tr><tr><td colspan="3"></td></tr></table></fsa:InformationOnCurrentDeferredTaxAssets>
<fsa:ExplanationOfPrepayments contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="1" align="left" valign="middle" >Prepayments</td></tr><tr><td width="100%" colspan="1" align="left" valign="middle" >Prepayments include accrual of expenses relating to subsequent financial years, including payments for market data, congresses and software licenses.</td></tr><tr><td colspan="1"></td></tr></table></fsa:ExplanationOfPrepayments>
<fsa:DisclosureOfContributedCapital contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="3" align="left" valign="middle" >Share capital</td></tr><tr><td width="100%" colspan="3" align="left" valign="middle" >All amounts in DKK.</td></tr><tr><td width="24%" ></td><td width="37%" align="right" valign="middle" >2020</td><td width="39%" align="right" valign="middle" >2019</td></tr><tr><td width="100%" colspan="3" align="left" valign="middle" >Change in the share capital over the past 3 years</td></tr><tr><td colspan="3"></td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Share capital 1 January</td><td width="37%" align="right" valign="middle" >500.000</td><td width="39%" align="right" valign="middle" >500.000</td></tr><tr><td width="24%" ></td><td width="37%" align="right" valign="middle" >500.000</td><td width="39%" align="right" valign="middle" >500.000</td></tr><tr><td colspan="3"></td></tr><tr><td width="100%" colspan="3" align="left" valign="middle" >The Company was founded 14. November 2016 and there has been no change in the share capital.</td></tr><tr><td colspan="3"></td></tr></table></fsa:DisclosureOfContributedCapital>
<fsa:DisclosureOfOtherProvisions contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="1" align="left" valign="middle" >Other provisions</td></tr><tr><td width="100%" colspan="1" align="left" valign="middle" >Other provisions comprise provisions for anniversary bonuses, totalling DKK 2.599.242.</td></tr><tr><td colspan="1"></td></tr></table></fsa:DisclosureOfOtherProvisions>
<fsa:DisclosureOfLongtermLiabilities contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="3" align="left" valign="middle" >Lease liabilities.</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Share of liabilities due within one year</td><td width="37%" align="right" valign="middle" >8.640.574</td><td width="39%" align="right" valign="middle" >6.299.404</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Share of liabilities due between one and five years</td><td width="37%" align="right" valign="middle" >10.267.937</td><td width="39%" align="right" valign="middle" >13.398.922</td></tr><tr><td width="24%" colspan="1" align="left" valign="middle" >Share of liabilities due after five years</td><td width="37%" align="right" valign="middle" >0</td><td width="39%" align="right" valign="middle" >0</td></tr><tr><td width="24%" ></td><td width="37%" align="right" valign="middle" >18.908.511</td><td width="39%" align="right" valign="middle" >19.693.326</td></tr><tr><td colspan="3"></td></tr></table></fsa:DisclosureOfLongtermLiabilities>
<fsa:OtherDisclosures contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="2" align="left" valign="middle" >Implementation of IFRS 16</td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >All amounts in DKK.</td></tr><tr><td colspan="2"></td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >The implementation of IFRS 16 in Novo Nordisk Denmark A/S increased the company's right-to use assets and lease liabilities. The impact on the adoption of IFRS 16 January 1, 2020 is shown below</td></tr><tr><td colspan="2"></td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >Minimum lease commitments</td><td width="61%" colspan="1" align="right" valign="middle" >1 January 2020</td></tr><tr><td colspan="2"></td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >Property</td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >Within one year</td><td width="61%" align="right" valign="middle" >5.537.135</td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >Between one and five years</td><td width="61%" align="right" valign="middle" >4.642.556</td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >Beyond five years</td><td width="61%" colspan="1" align="right" valign="middle" >-</td></tr><tr><td width="39%" ></td><td width="61%" align="right" valign="middle" >10.179.691</td></tr><tr><td colspan="2"></td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >Other fixtures and fittings, tools and equipment</td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >Within one year</td><td width="61%" align="right" valign="middle" >3.103.440</td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >Between one and five years</td><td width="61%" align="right" valign="middle" >5.487.338</td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >Beyond five years</td><td width="61%" colspan="1" align="right" valign="middle" >-</td></tr><tr><td width="39%" ></td><td width="61%" align="right" valign="middle" >8.590.778</td></tr><tr><td colspan="2"></td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >Total minimum lease commitments</td><td width="61%" colspan="1" align="right" valign="middle" >-</td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >Low-value leases and short-term leases excluded</td><td width="61%" colspan="1" align="right" valign="middle" >-</td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >Discounted to present value</td><td width="61%" colspan="1" align="right" valign="middle" >-</td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >To be capitalised as right-of-use assets at l January 2020</td><td width="61%" colspan="1" align="right" valign="middle" >-</td></tr><tr><td colspan="2"></td></tr></table></fsa:OtherDisclosures>
<fsa:DisclosureOfContingentLiabilities contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="1" align="left" valign="middle" >Contractual obligations and contingencies, etc. Other contingent liabilities</td></tr><tr><td width="100%" colspan="1" align="left" valign="middle" >All amounts in DKK.</td></tr><tr><td colspan="1"></td></tr><tr><td width="100%" colspan="1" align="left" valign="middle" >The Company is jointly taxed with its parent, Novo Nordisk A/S, which acts' as management company, and is jointly and severally liable with other jointly taxed group entities for payment of income taxes for the income year 2020 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 14 November 2017.</td></tr><tr><td colspan="1"></td></tr></table></fsa:DisclosureOfContingentLiabilities>
<fsa:DisclosureOfRelatedParties contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="2" align="left" valign="middle" >Related parties</td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >Controlling interest</td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >Related party</td><td width="61%" colspan="1" align="right" valign="middle" >Basis for control</td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >Novo Nordisk Region Europe A/S</td><td width="61%" colspan="1" align="right" valign="middle" >Participating interest</td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >Novo Alle 1</td><td width="61%" colspan="1" align="right" valign="middle" >Shareholders' agreement</td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >2880 Bagsværd</td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >Denmark</td></tr><tr><td colspan="2"></td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >Information about consolidated financial statement</td></tr><tr><td colspan="2"></td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >Parent</td><td width="61%" colspan="1" align="right" valign="middle" >Requisitioning of the</td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >Novo Nordisk A/S</td><td width="61%" colspan="1" align="right" valign="middle" >parent company's</td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >Novo Alle 1</td><td width="61%" colspan="1" align="right" valign="middle" >consolidated financial</td></tr><tr><td width="39%" colspan="1" align="left" valign="middle" >2820 Bagsværd</td><td width="61%" colspan="1" align="right" valign="middle" >statements</td></tr><tr><td width="39%" ></td><td width="61%" colspan="1" align="right" valign="middle" >www.novonordisk.dk</td></tr><tr><td colspan="2"></td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >Other related parties</td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >The Company solely discloses related party transactions that have not been carried out on an arm's length basis, cf. section 98c(7) of the Danish Financial Statements Act.</td></tr><tr><td colspan="2"></td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >All transactions have been carried out on an arm's length basis.</td></tr></table></fsa:DisclosureOfRelatedParties>
<gsd:InformationOnTypeOfSubmittedReport contextRef="ctx1">Ã
rsrapport</gsd:InformationOnTypeOfSubmittedReport>
<gsd:IdentificationNumberCvrOfSubmittingEnterprise contextRef="ctx1">38180045</gsd:IdentificationNumberCvrOfSubmittingEnterprise>
<gsd:NameOfSubmittingEnterprise contextRef="ctx1" xml:lang="da">Novo Nordisk Denmark A/S</gsd:NameOfSubmittingEnterprise>
<gsd:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="ctx1" xml:lang="da">Ãrestads Boulevard 108</gsd:AddressOfSubmittingEnterpriseStreetAndNumber>
<gsd:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="ctx1" xml:lang="da">2300 København S</gsd:AddressOfSubmittingEnterprisePostcodeAndTown>
<gsd:ToolForPreparingTheXBRLInstanceDocument contextRef="ctx1" xml:lang="da">xWizard version 1.1.1028.0, by EasyX Aps. www.easyx.eu</gsd:ToolForPreparingTheXBRLInstanceDocument>
<gsd:PrecedingReportingPeriodStartDate contextRef="ctx1">2019-01-01</gsd:PrecedingReportingPeriodStartDate>
<gsd:PredingReportingPeriodEndDate contextRef="ctx1">2019-12-31</gsd:PredingReportingPeriodEndDate>
<cmn:TypeOfAuditorAssistance contextRef="ctx1">Revisionspåtegning</cmn:TypeOfAuditorAssistance>
<cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx2" xml:lang="da">Kasper Bødker Mejlvang</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx3" xml:lang="da">Frederik Kier</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx3" xml:lang="da">Chairman</cmn:TitleOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx4" xml:lang="da">Tomas Haagen</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx5" xml:lang="da">Morten Engelund</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<fsa:Revenue contextRef="ctx6" unitRef="vDKK" decimals="-3">363936000</fsa:Revenue>
<fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx6" unitRef="vDKK" decimals="-3">8811000</fsa:ProfitLossFromOrdinaryOperatingActivities>
<fsa:ResultsFromNetFinancials contextRef="ctx6" unitRef="vDKK" decimals="-3">-511000</fsa:ResultsFromNetFinancials>
<fsa:ProfitLoss contextRef="ctx6" unitRef="vDKK" decimals="-3">5252000</fsa:ProfitLoss>
<fsa:InvestmentInPropertyPlantAndEquipment contextRef="ctx6" unitRef="vDKK" decimals="-3">0</fsa:InvestmentInPropertyPlantAndEquipment>
<fsa:AverageNumberOfEmployees contextRef="ctx6" unitRef="pure" decimals="2">65</fsa:AverageNumberOfEmployees>
<mrv:OperatingMargin contextRef="ctx6" unitRef="pure" decimals="3">0.024</mrv:OperatingMargin>
<mrv:GrossMargin contextRef="ctx6" unitRef="pure" decimals="3">0.371</mrv:GrossMargin>
<mrv:ReturnOnEquity contextRef="ctx6" unitRef="pure" decimals="3">0.413</mrv:ReturnOnEquity>
<mrv:EquityRatio contextRef="ctx6" unitRef="pure" decimals="3">0.103</mrv:EquityRatio>
<fsa:Revenue contextRef="ctx7" unitRef="vDKK" decimals="-3">341939000</fsa:Revenue>
<fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx7" unitRef="vDKK" decimals="-3">6162000</fsa:ProfitLossFromOrdinaryOperatingActivities>
<fsa:ResultsFromNetFinancials contextRef="ctx7" unitRef="vDKK" decimals="-3">87000</fsa:ResultsFromNetFinancials>
<fsa:ProfitLoss contextRef="ctx7" unitRef="vDKK" decimals="-3">4213000</fsa:ProfitLoss>
<fsa:InvestmentInPropertyPlantAndEquipment contextRef="ctx7" unitRef="vDKK" decimals="-3">0</fsa:InvestmentInPropertyPlantAndEquipment>
<fsa:AverageNumberOfEmployees contextRef="ctx7" unitRef="pure" decimals="2">69</fsa:AverageNumberOfEmployees>
<mrv:OperatingMargin contextRef="ctx7" unitRef="pure" decimals="3">0.018</mrv:OperatingMargin>
<mrv:GrossMargin contextRef="ctx7" unitRef="pure" decimals="3">0.349</mrv:GrossMargin>
<mrv:ReturnOnEquity contextRef="ctx7" unitRef="pure" decimals="3">0.528</mrv:ReturnOnEquity>
<mrv:EquityRatio contextRef="ctx7" unitRef="pure" decimals="3">0.078</mrv:EquityRatio>
<fsa:Revenue contextRef="ctx8" unitRef="vDKK" decimals="-3">317443000</fsa:Revenue>
<fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx8" unitRef="vDKK" decimals="-3">6888000</fsa:ProfitLossFromOrdinaryOperatingActivities>
<fsa:ResultsFromNetFinancials contextRef="ctx8" unitRef="vDKK" decimals="-3">198000</fsa:ResultsFromNetFinancials>
<fsa:ProfitLoss contextRef="ctx8" unitRef="vDKK" decimals="-3">5379000</fsa:ProfitLoss>
<fsa:InvestmentInPropertyPlantAndEquipment contextRef="ctx8" unitRef="vDKK" decimals="-3">1769000</fsa:InvestmentInPropertyPlantAndEquipment>
<fsa:AverageNumberOfEmployees contextRef="ctx8" unitRef="pure" decimals="2">52</fsa:AverageNumberOfEmployees>
<mrv:OperatingMargin contextRef="ctx8" unitRef="pure" decimals="3">0.022</mrv:OperatingMargin>
<mrv:GrossMargin contextRef="ctx8" unitRef="pure" decimals="3">0.352</mrv:GrossMargin>
<mrv:ReturnOnEquity contextRef="ctx8" unitRef="pure" decimals="3">0.915</mrv:ReturnOnEquity>
<mrv:EquityRatio contextRef="ctx8" unitRef="pure" decimals="3">0.047</mrv:EquityRatio>
<fsa:Assets contextRef="ctx9" unitRef="vDKK" decimals="0">584971435</fsa:Assets>
<fsa:Equity contextRef="ctx9" unitRef="vDKK" decimals="0">36587365</fsa:Equity>
<fsa:LandAndBuildings contextRef="ctx9" unitRef="vDKK" decimals="0">10179691</fsa:LandAndBuildings>
<fsa:FixturesFittingsToolsAndEquipment contextRef="ctx9" unitRef="vDKK" decimals="0">11004790</fsa:FixturesFittingsToolsAndEquipment>
<fsa:PropertyPlantAndEquipment contextRef="ctx9" unitRef="vDKK" decimals="0">21184481</fsa:PropertyPlantAndEquipment>
<fsa:NoncurrentAssets contextRef="ctx9" unitRef="vDKK" decimals="0">21184481</fsa:NoncurrentAssets>
<fsa:ShorttermTradeReceivables contextRef="ctx9" unitRef="vDKK" decimals="0">50866692</fsa:ShorttermTradeReceivables>
<fsa:ShorttermReceivablesFromGroupEnterprises contextRef="ctx9" unitRef="vDKK" decimals="0">171815862</fsa:ShorttermReceivablesFromGroupEnterprises>
<fsa:CurrentDeferredTaxAssets contextRef="ctx9" unitRef="vDKK" decimals="0">2395620</fsa:CurrentDeferredTaxAssets>
<fsa:ShorttermTaxReceivables contextRef="ctx9" unitRef="vDKK" decimals="0">0</fsa:ShorttermTaxReceivables>
<fsa:OtherShorttermReceivables contextRef="ctx9" unitRef="vDKK" decimals="0">3861493</fsa:OtherShorttermReceivables>
<fsa:DeferredIncomeAssets contextRef="ctx9" unitRef="vDKK" decimals="0">8372917</fsa:DeferredIncomeAssets>
<fsa:ShorttermReceivables contextRef="ctx9" unitRef="vDKK" decimals="0">237312584</fsa:ShorttermReceivables>
<fsa:CashAndCashEquivalents contextRef="ctx9" unitRef="vDKK" decimals="0">326474370</fsa:CashAndCashEquivalents>
<fsa:CurrentAssets contextRef="ctx9" unitRef="vDKK" decimals="0">563786954</fsa:CurrentAssets>
<fsa:ContributedCapital contextRef="ctx9" unitRef="vDKK" decimals="0">500000</fsa:ContributedCapital>
<fsa:RetainedEarnings contextRef="ctx9" unitRef="vDKK" decimals="0">15087365</fsa:RetainedEarnings>
<fsa:ProposedDividendRecognisedInEquity contextRef="ctx9" unitRef="vDKK" decimals="0">21000000</fsa:ProposedDividendRecognisedInEquity>
<fsa:OtherProvisions contextRef="ctx9" unitRef="vDKK" decimals="0">2599242</fsa:OtherProvisions>
<fsa:Provisions contextRef="ctx9" unitRef="vDKK" decimals="0">2599242</fsa:Provisions>
<fsa:LongtermLeaseCommitments contextRef="ctx9" unitRef="vDKK" decimals="0">18908511</fsa:LongtermLeaseCommitments>
<fsa:LongtermLiabilitiesOtherThanProvisions contextRef="ctx9" unitRef="vDKK" decimals="0">18908511</fsa:LongtermLiabilitiesOtherThanProvisions>
<fsa:ShorttermTradePayables contextRef="ctx9" unitRef="vDKK" decimals="0">25481550</fsa:ShorttermTradePayables>
<fsa:ShorttermPayablesToGroupEnterprises contextRef="ctx9" unitRef="vDKK" decimals="0">375870174</fsa:ShorttermPayablesToGroupEnterprises>
<fsa:ShorttermTaxPayables contextRef="ctx9" unitRef="vDKK" decimals="0">6954098</fsa:ShorttermTaxPayables>
<fsa:OtherShorttermPayables contextRef="ctx9" unitRef="vDKK" decimals="0">118570495</fsa:OtherShorttermPayables>
<fsa:ShorttermLiabilitiesOtherThanProvisions contextRef="ctx9" unitRef="vDKK" decimals="0">526876317</fsa:ShorttermLiabilitiesOtherThanProvisions>
<fsa:LiabilitiesOtherThanProvisions contextRef="ctx9" unitRef="vDKK" decimals="0">545784828</fsa:LiabilitiesOtherThanProvisions>
<fsa:LiabilitiesAndEquity contextRef="ctx9" unitRef="vDKK" decimals="0">584971435</fsa:LiabilitiesAndEquity>
<fsa:Assets contextRef="ctx10" unitRef="vDKK" decimals="-3">149608000</fsa:Assets>
<fsa:Equity contextRef="ctx10" unitRef="vDKK" decimals="-3">15343000</fsa:Equity>
<fsa:Assets contextRef="ctx11" unitRef="vDKK" decimals="-3">130040000</fsa:Assets>
<fsa:Equity contextRef="ctx11" unitRef="vDKK" decimals="-3">10092000</fsa:Equity>
<fsa:Assets contextRef="ctx12" unitRef="vDKK" decimals="-3">124799000</fsa:Assets>
<fsa:Equity contextRef="ctx12" unitRef="vDKK" decimals="-3">5879000</fsa:Equity>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx13" xml:lang="da">EBITDA-margin</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx13" unitRef="pure" decimals="3">0.045</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx14" xml:lang="da">EBITDA-margin</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx14" unitRef="pure" decimals="3">0.024</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx15" xml:lang="da">EBITDA-margin</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx15" unitRef="pure" decimals="3">0.019</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx16" xml:lang="da">EBITDA-margin</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx16" unitRef="pure" decimals="3">0.022</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx17" xml:lang="da">Return on assets</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx17" unitRef="pure" decimals="3">0.078</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx18" xml:lang="da">Return on assets</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx18" unitRef="pure" decimals="3">0.063</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx19" xml:lang="da">Return on assets</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx19" unitRef="pure" decimals="3">0.048</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx20" xml:lang="da">Return on assets</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx20" unitRef="pure" decimals="3">0.055</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx21" xml:lang="da">Current ratio</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx21" unitRef="pure" decimals="2">1.07</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx22" xml:lang="da">Current ratio</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx22" unitRef="pure" decimals="3">1.115</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx23" xml:lang="da">Current ratio</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx23" unitRef="pure" decimals="3">1.081</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx24" xml:lang="da">Current ratio</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx24" unitRef="pure" decimals="3">1.044</mrv:ValueOfKeyFigureOrFinancialRatio>
<fsa:Revenue contextRef="ctx25" unitRef="vDKK" decimals="0">363935810</fsa:Revenue>
<fsa:OtherOperatingIncome contextRef="ctx25" unitRef="vDKK" decimals="0">112489</fsa:OtherOperatingIncome>
<fsa:CostOfSales contextRef="ctx25" unitRef="vDKK" decimals="0">28314565</fsa:CostOfSales>
<fsa:OtherExternalExpenses contextRef="ctx25" unitRef="vDKK" decimals="0">200847324</fsa:OtherExternalExpenses>
<fsa:GrossResult contextRef="ctx25" unitRef="vDKK" decimals="0">134886410</fsa:GrossResult>
<fsa:EmployeeBenefitsExpense contextRef="ctx25" unitRef="vDKK" decimals="0">125898522</fsa:EmployeeBenefitsExpense>
<fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="ctx25" unitRef="vDKK" decimals="0">176851</fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss>
<fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx25" unitRef="vDKK" decimals="0">8811037</fsa:ProfitLossFromOrdinaryOperatingActivities>
<fsa:OtherFinanceIncome contextRef="ctx25" unitRef="vDKK" decimals="0">398140</fsa:OtherFinanceIncome>
<fsa:OtherFinanceExpenses contextRef="ctx25" unitRef="vDKK" decimals="0">909538</fsa:OtherFinanceExpenses>
<fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx25" unitRef="vDKK" decimals="0">8299639</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
<fsa:TaxExpense contextRef="ctx25" unitRef="vDKK" decimals="0">3047829</fsa:TaxExpense>
<fsa:ProfitLoss contextRef="ctx25" unitRef="vDKK" decimals="0">5251810</fsa:ProfitLoss>
<fsa:LandAndBuildings contextRef="ctx26" unitRef="vDKK" decimals="0">0</fsa:LandAndBuildings>
<fsa:FixturesFittingsToolsAndEquipment contextRef="ctx26" unitRef="vDKK" decimals="0">1329741</fsa:FixturesFittingsToolsAndEquipment>
<fsa:PropertyPlantAndEquipment contextRef="ctx26" unitRef="vDKK" decimals="0">1329741</fsa:PropertyPlantAndEquipment>
<fsa:NoncurrentAssets contextRef="ctx26" unitRef="vDKK" decimals="0">1329741</fsa:NoncurrentAssets>
<fsa:ShorttermTradeReceivables contextRef="ctx26" unitRef="vDKK" decimals="0">274376</fsa:ShorttermTradeReceivables>
<fsa:ShorttermReceivablesFromGroupEnterprises contextRef="ctx26" unitRef="vDKK" decimals="0">4168617</fsa:ShorttermReceivablesFromGroupEnterprises>
<fsa:CurrentDeferredTaxAssets contextRef="ctx26" unitRef="vDKK" decimals="0">998202</fsa:CurrentDeferredTaxAssets>
<fsa:ShorttermTaxReceivables contextRef="ctx26" unitRef="vDKK" decimals="0">880604</fsa:ShorttermTaxReceivables>
<fsa:OtherShorttermReceivables contextRef="ctx26" unitRef="vDKK" decimals="0">5870</fsa:OtherShorttermReceivables>
<fsa:DeferredIncomeAssets contextRef="ctx26" unitRef="vDKK" decimals="0">4789060</fsa:DeferredIncomeAssets>
<fsa:ShorttermReceivables contextRef="ctx26" unitRef="vDKK" decimals="0">11116729</fsa:ShorttermReceivables>
<fsa:CashAndCashEquivalents contextRef="ctx26" unitRef="vDKK" decimals="0">137161043</fsa:CashAndCashEquivalents>
<fsa:CurrentAssets contextRef="ctx26" unitRef="vDKK" decimals="0">148277772</fsa:CurrentAssets>
<fsa:Assets contextRef="ctx26" unitRef="vDKK" decimals="0">149607513</fsa:Assets>
<fsa:ContributedCapital contextRef="ctx26" unitRef="vDKK" decimals="0">500000</fsa:ContributedCapital>
<fsa:RetainedEarnings contextRef="ctx26" unitRef="vDKK" decimals="0">14843476</fsa:RetainedEarnings>
<fsa:ProposedDividendRecognisedInEquity contextRef="ctx26" unitRef="vDKK" decimals="0">0</fsa:ProposedDividendRecognisedInEquity>
<fsa:Equity contextRef="ctx26" unitRef="vDKK" decimals="0">15343476</fsa:Equity>
<fsa:OtherProvisions contextRef="ctx26" unitRef="vDKK" decimals="0">1261926</fsa:OtherProvisions>
<fsa:Provisions contextRef="ctx26" unitRef="vDKK" decimals="0">1261926</fsa:Provisions>
<fsa:LongtermLeaseCommitments contextRef="ctx26" unitRef="vDKK" decimals="0">0</fsa:LongtermLeaseCommitments>
<fsa:LongtermLiabilitiesOtherThanProvisions contextRef="ctx26" unitRef="vDKK" decimals="0">0</fsa:LongtermLiabilitiesOtherThanProvisions>
<fsa:ShorttermTradePayables contextRef="ctx26" unitRef="vDKK" decimals="0">12911863</fsa:ShorttermTradePayables>
<fsa:ShorttermPayablesToGroupEnterprises contextRef="ctx26" unitRef="vDKK" decimals="0">37286109</fsa:ShorttermPayablesToGroupEnterprises>
<fsa:ShorttermTaxPayables contextRef="ctx26" unitRef="vDKK" decimals="0">0</fsa:ShorttermTaxPayables>
<fsa:OtherShorttermPayables contextRef="ctx26" unitRef="vDKK" decimals="0">82804139</fsa:OtherShorttermPayables>
<fsa:ShorttermLiabilitiesOtherThanProvisions contextRef="ctx26" unitRef="vDKK" decimals="0">133002111</fsa:ShorttermLiabilitiesOtherThanProvisions>
<fsa:LiabilitiesOtherThanProvisions contextRef="ctx26" unitRef="vDKK" decimals="0">133002111</fsa:LiabilitiesOtherThanProvisions>
<fsa:LiabilitiesAndEquity contextRef="ctx26" unitRef="vDKK" decimals="0">149607513</fsa:LiabilitiesAndEquity>
<fsa:ProfitLoss contextRef="ctx27" unitRef="vDKK" decimals="0">21000000</fsa:ProfitLoss>
<fsa:ProfitLoss contextRef="ctx28" unitRef="vDKK" decimals="0">0</fsa:ProfitLoss>
<fsa:ProfitLoss contextRef="ctx29" unitRef="vDKK" decimals="0">277960</fsa:ProfitLoss>
<fsa:ProfitLoss contextRef="ctx30" unitRef="vDKK" decimals="0">5251810</fsa:ProfitLoss>
<cmn:NameOfAuditFirm contextRef="ctx31" xml:lang="da">PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab</cmn:NameOfAuditFirm>
<cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx31">33771231</cmn:IdentificationNumberCvrOfAuditFirm>
<cmn:NameAndSurnameOfAuditor contextRef="ctx31" xml:lang="da">Mads Melgaard</cmn:NameAndSurnameOfAuditor>
<cmn:DescriptionOfAuditor contextRef="ctx31" xml:lang="da">State authorized public Accountant</cmn:DescriptionOfAuditor>
<cmn:IdentificationNumberOfAuditor contextRef="ctx31">mne34354</cmn:IdentificationNumberOfAuditor>
<gsd:AddressOfAuditorStreetName contextRef="ctx31" xml:lang="da">Strandvejen</gsd:AddressOfAuditorStreetName>
<gsd:AddressOfAuditorStreetBuildingIdentifier contextRef="ctx31" xml:lang="da">44</gsd:AddressOfAuditorStreetBuildingIdentifier>
<gsd:AddressOfAuditorPostCodeIdentifier contextRef="ctx31" xml:lang="da">2900</gsd:AddressOfAuditorPostCodeIdentifier>
<gsd:AddressOfAuditorDistrictName contextRef="ctx31" xml:lang="da">Hellerup</gsd:AddressOfAuditorDistrictName>
</xbrli:xbrl>